Aarti Surfactants Ltd. Overview
Aarti Surfactants Limited is a small-cap Indian maker of surfactants and specialty ingredients for home and personal care, carved out of Aarti Industries in 2019 and listed in 2020. From two plants at Pithampur and Silvassa, with roughly 113,000 tonnes a year of capacity, it supplies sulfonation products, betaines and milder specialty ingredients to consumer-goods majors including Hindustan Unilever, Procter & Gamble, Colgate-Palmolive, Dabur and ITC. It is one of the larger merchant suppliers in India, yet a fraction of the size of the domestic leader, Galaxy Surfactants. The business is volume-rich and margin-thin: cost-plus contracts pass palm-linked feedstock prices through to customers, so revenue swings with raw materials while operating margin has stayed in a 5 to 11 percent band. Two customers supplied about 71 percent of FY2026 revenue. The investment case rests on a multi-purpose plant under construction, a new R&D centre, and a slow shift toward higher-margin specialties.
What the company does. Aarti Surfactants manufactures ionic and non-ionic surfactants and specialty ingredients that go into detergents, dishwashing liquids, surface cleaners, shampoos, body washes, hand washes and skin-care formulations. The company describes itself on its website as one of the leading producers of ionic and non-ionic surfactants and specialty products, serving home and personal care, industrial applications, agro and oil industries in India and overseas. Its first annual report (FY2019) described a range of over 30 surfactants plus custom surfactants and formulated blends; the FY2025 annual report and the September 2026 AGM presentation cite 50+ products and 100+ customers.
Business model. This is a business-to-business process-chemistry operation. The company buys oleochemical and petrochemical feedstocks (chiefly lauryl alcohol, coconut fatty acid and alpha olefin), converts them through sulfonation, sulfation, amidation and related chemistries, and sells the output in bulk to consumer-goods formulators. Crisil states that core products are largely commoditised and sold under cost-plus arrangements with quarterly price resets. That structure makes the company closer to a tolling-style converter than a price-setting specialty house: absolute profit per tonne is relatively stable, while reported revenue and percentage margin move with feedstock prices.
Revenue model. Revenue is essentially 100 percent product sales. There is no disclosed service, subscription or licensing income. Other income is negligible in normal years; FY2025 included a one-time state industrial promotion incentive of INR 6.34 crore (Crisil).
Value chain position. The company sits midstream, between palm- and petro-based feedstock producers (largely import-linked) and branded FMCG formulators. It does not own upstream fatty alcohol capacity and does not sell consumer brands.
Customers and end-markets. Customers are multinational and domestic FMCG companies. CARE names Hindustan Unilever, Procter & Gamble Home Products, Colgate-Palmolive (India) and Dabur India; Crisil adds ITC. Supplier qualification takes 12 to 18 months according to Crisil, which protects incumbency. End-markets are home care (laundry, dishwash, surface care) and personal care (hair, bath, skin), with smaller sales to industrial, agrochemical and oilfield uses. Domestic sales were 82 percent of FY2026 revenue and exports 18 percent (AGM presentation summary).
Independent characterisation. The company is best understood as the second-tier Indian merchant surfactant supplier with a concentrated blue-chip customer book, a commodity-heavy mix, and a balance sheet that has been repaired since 2022. Its strategic question is whether new capacity and R&D can lift the specialty share enough to move operating margin sustainably above the mid-single digits.
Strategy
Stated themes. Management's published messaging (FY2025 annual report; September 2026 AGM presentation, as summarised in exchange-filing coverage) centres on five themes, paraphrased here: (1) research and innovation as the basis of the company's value proposition in specialty surfactants; (2) quality, innovation and customer-centricity to be a trusted supplier of high-performance surfactants; (3) digital and process automation to raise plant uptime and efficiency; (4) capacity utilisation and operating efficiency to defend margins against input-cost, freight and pricing pressure; and (5) expansion in higher-margin skin-care ingredients.
Initiatives announced in the last 24 months
Cost programmes. No quantified cost-reduction programme has been disclosed.
Medium-term financial targets. The company has not published numerical guidance in the sources reviewed. The only forward numbers in the public domain are rating-agency expectations: Crisil expects net cash accrual above INR 40 crore in FY2027 and INR 42 to 50 crore a year thereafter, interest cover of 5 to 7 times, gearing of 0.35 to 0.40 times over the medium term, and ROCE moving to double digits.
Reading the objects-clause change. The widened memorandum is an enabling step and not a business plan. Combined with the appointment of a pharmaceutics professor as independent director, a multi-purpose plant and a US entity named "Precision Ingredients", it points toward a deliberate move into higher-value ingredients adjacent to pharma and personal care. No capex, product or customer announcement supports that reading yet.
Products & Services
The company does not publish a priced catalogue, and launch years and specifications by product are not disclosed in the sources reviewed. The table sets out product families named in company, CARE and Crisil descriptions. Chemical examples in the "typical chemistry" column are standard industry examples for the family and should be confirmed against the company's product list before being attributed to it.
Sources: Business Standard/Capital Market company description (May 2026); CARE Ratings (December 2025); Crisil (September 2026); company website; FY2019 Annual Report.
Flagship offerings. By volume, the flagship lines are the sulfonation products sold to the two largest customers. By strategic emphasis, management points to skin-care ingredients as the high-margin growth area (AGM presentation summary). Named brand or trade names for individual products are not publicly disclosed in the sources reviewed.
Services. No standalone service lines are disclosed. Custom synthesis and formulation support are embedded in product sales.
Product Portfolio
| Product family | What it is | Typical chemistry (industry examples) | Main use | Target customer | Pricing model |
|---|---|---|---|---|---|
Sulfonation products (anionic surfactants) | Primary cleansing and foaming agents; the company's volume backbone, made at the Pithampur sulfonation unit | Sulfonated and sulfated compounds derived from lauryl alcohol and alpha olefin | Detergents, dishwash liquids, shampoos, body and hand washes | Large FMCG formulators | Cost-plus with quarterly resets (Crisil) |
CAPB and amphoteric surfactants | Secondary surfactants that add mildness and foam stability | Cocamidopropyl betaine from coconut fatty acid | Shampoos, body washes, hand washes | FMCG personal care | — |
Mild surfactants | Low-irritation cleansers for premium and baby care | — | Face wash, baby care, sulfate-free formulations | Personal care brands | — |
Non-ionic surfactants | Emulsifiers and foam boosters | — | Home care, personal care, industrial uses | FMCG and industrial | — |
Rheology modifiers | Thickeners and viscosity builders | — | Liquid cleansers | Personal care | — |
Pearlising agents | Give opacity and pearl effect | — | Shampoos, body washes | Personal care | — |
UV filters | Sun-protection actives | — | Sun care and skin care | Skin care brands | — |
Syndet and soap bases | Bases for synthetic detergent bars and soaps | — | Bathing bars | Soap makers | — |
Conditioning agents and quats | Cationic conditioning ingredients | — | Hair conditioners, fabric care | Personal and fabric care | — |
Proteins and active ingredients | Functional actives | — | Hair and skin care | Personal care | — |
Blends and custom surfactants | Formulated blends and made-to-order surfactants | Customer specific | Customer formulations | Key accounts | — |
Industrial, agro and oilfield surfactants | Surfactants for non-HPC uses | — | Agrochemical formulation, oil industry, industrial cleaning | Industrial buyers | — |
“—” = not publicly disclosed.
Financial Narrative
All figures consolidated, INR crore unless stated. Source: Screener.in (from filed results), with decimals from the Anand Rathi results table where available. Gross profit is not reported in the sources reviewed (Indian results show cost of materials rather than gross profit), so no gross profit row is given.
Income statement
Diluted EPS is not separately shown by the aggregator; the standalone diluted EPS reported in the AGM presentation was INR 17.71 for FY2025 and INR 14.96 for FY2026.
Revenue CAGR: 10.5 percent over FY2022 to FY2026 (four years, derived); 13 percent over FY2021 to FY2026 (five years, Screener).
Commentary. Three things stand out. First, revenue is a poor guide to earnings. FY2026 revenue was 49 percent above FY2022, yet EBIT was only about INR 9 crore higher. Second, the margin cycle follows feedstock. FY2024 benefited from falling input costs against lagged prices; FY2025 and FY2026 saw the reverse as fatty alcohol prices climbed sharply (Galaxy Surfactants reported average fatty alcohol prices rising from about USD 1,926 per tonne in Q2 FY2025 to about USD 2,800 in Q2 FY2026). CARE states plainly that the company had limited ability to pass on the increases in time. Third, fixed charges are heavy relative to EBITDA: depreciation plus interest consumed INR 30 crore of INR 47 crore of FY2026 EBITDA, which is why small margin moves produce large swings in net profit.
Balance sheet
Debt split (FY2025 Directors' Report, consolidated). Long-term borrowings, including the 0% preference shares, were INR 27.60 crore at 31 March 2025 against INR 47.93 crore a year earlier. Short-term borrowings were INR 81.13 crore against INR 49.29 crore.
Cash and net debt. Crisil reports an unencumbered liquid surplus of INR 13 crore at 31 March 2026, implying net debt of roughly INR 90 crore.
Goodwill and intangibles. No goodwill is evident (the company has made no acquisitions). Intangible assets are not separately shown in the sources reviewed.
Working capital. Screener shows working capital days of 16, 20, 40, 36 and 22 for FY2022 to FY2026.
Commentary. Leverage has roughly halved in relative terms. Debt to equity fell from 1.19 times in FY2022 to 0.43 times in FY2026, helped by the 2023 rights issue (equity rose by about INR 48 crore more than retained profit across FY2023 and FY2024, consistent with staged receipt of issue proceeds) and by strong FY2024 cash flow. CWIP rising to INR 45 crore in FY2026 marks the start of the new capex cycle. Payables growth (other liabilities up INR 34 crore in FY2026) funded much of the higher-priced inventory and receivables.
Cash flow
Dividends paid: none in FY2022 to FY2025; the INR 1 per share dividend for FY2025 (about INR 0.85 crore) was paid in FY2026, and the same amount for FY2026 was approved on 29 September 2026. No buyback has been announced.
Commentary. FY2026 operating cash flow of INR 77 crore was 1.7 times operating profit, driven by a release of inventory days (92 to 60) and higher payables. That working capital benefit is unlikely to repeat at the same scale. FY2025 was the mirror image: inventory build at rising prices cut operating cash flow to INR 11 crore.
Ratios
Net debt to EBITDA for FY2026 is about 1.9 times using Crisil's INR 13 crore liquid surplus.
Rating-agency versions of the same ratios. Crisil: adjusted gearing 0.43 times (FY2026) and 0.47 times (FY2025); interest coverage 3.85 times and 3.95 times; ROCE 8.2 percent in FY2026. CARE: total debt to PBILDT 1.60 times (FY2024), 3.18 times (FY2025), 2.80 times (H1 FY2026); interest coverage 4.41, 3.00 and 3.46 times. The AGM presentation (standalone) shows ROCE falling from 11.54 percent to 9.72 percent and ROE from 6.61 percent to 5.27 percent. The differences reflect each party's definitions.
Commentary. Returns are below any reasonable cost of capital in four of five years. ROE has averaged about 7 percent. The single year above 10 percent (FY2024) needed a favourable feedstock tailwind. The improvement the company can point to is in balance-sheet risk, not in returns.
Recent quarters (consolidated, INR crore)
Source: Screener. Q1 FY2027 (quarter ended 30 June 2026) was the strongest quarter since Q4 FY2025; Crisil notes the margin improvement included inventory gains that it expects to be temporary.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue: HPC surfactants and specialty ingredients (INR Cr) | 589.86 | 659.09 | 859.13 |
YoY revenue growth (%) | -1.9 | 11.7 | 30.3 |
Share of total revenue (%) | 100 | 100 | 100 |
Operating profit before other income, depreciation and interest (INR Cr) | 62 | 42 | 47 |
Operating margin (%) | 10.5 | 6.4 | 5.5 |
Pre-tax profit (INR Cr) | 32.19 | 20.70 | 17.22 |
Pre-tax margin (%) | 5.5 | 3.1 | 2.0 |
Income Statement and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 575.52 | 601.29 | 589.86 | 659.09 | 859.13 |
Operating profit before other income (INR Cr) | 32 | 48 | 62 | 42 | 47 |
Other income (INR Cr) | 0 | 0 | 0 | 8 | 0 |
EBITDA including other income (INR Cr) | 32 | 48 | 62 | 50 | 47 |
Depreciation (INR Cr) | 12 | 15 | 16 | 17 | 18 |
Operating income, EBIT (INR Cr, derived) | 20 | 33 | 46 | 33 | 29 |
Interest (INR Cr) | 11 | 15 | 14 | 12 | 12 |
Pre-tax income (INR Cr) | 9.32 | 17.80 | 32.19 | 20.70 | 17.22 |
Net income (INR Cr) | 5.49 | 12.70 | 21.33 | 14.55 | 12.34 |
EPS, basic (INR) | 6.46 | 14.94 | 25.22 | 17.19 | 14.58 |
Dividend per share (INR) | 0 | 0 | 0 | 1 | 1 |
Margin / growth
| Margin / growth | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue growth (%) | 23.6 | 4.5 | -1.9 | 11.7 | 30.3 |
Operating margin before other income (%) | 5.6 | 8.0 | 10.5 | 6.4 | 5.5 |
EBITDA margin including other income (%) | 5.6 | 8.0 | 10.6 | 7.5 | 5.5 |
EBIT margin (%) | 3.5 | 5.5 | 7.8 | 5.0 | 3.4 |
Net margin (%) | 1.0 | 2.1 | 3.6 | 2.2 | 1.4 |
Effective tax rate (%) | 41 | 29 | 34 | 30 | 28 |
Balance Sheet
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets | 402 | 404 | 422 | 477 | 517 |
Net fixed assets (incl. intangibles) | 173 | 207 | 208 | 204 | 200 |
Capital work in progress | 52 | 8 | 8 | 15 | 45 |
Other assets (mainly current) | 178 | 188 | 206 | 259 | 272 |
Total debt | 162 | 149 | 99 | 110 | 104 |
Shareholders' equity (capital plus reserves) | 136 | 168 | 218 | 232 | 244 |
Other liabilities (mainly payables) | 105 | 86 | 105 | 134 | 168 |
Cash Flow
| Metric (INR Cr) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Operating cash flow | 23 | 25 | 52 | 11 | 77 |
Investing cash flow | -23 | -11 | -16 | -16 | -46 |
Financing cash flow | -6 | -8 | -37 | 0 | -19 |
Net cash flow | -5 | 6 | -1 | -5 | 12 |
Free cash flow (Screener definition) | 1 | 14 | 36 | -9 | 32 |
Capex (derived: operating cash flow minus free cash flow) | 22 | 11 | 16 | 20 | 45 |
Buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROCE (%) (Screener) | 7 | 11 | 15 | 8 | 9 |
ROE (%) (derived, on average equity) | 4.1 | 8.4 | 11.1 | 6.5 | 5.2 |
ROA (%) (derived, on average assets) | 1.4 | 3.2 | 5.2 | 3.2 | 2.5 |
Debt / equity (x) (derived) | 1.19 | 0.89 | 0.45 | 0.47 | 0.43 |
Gross debt / EBITDA (x) (derived) | 5.0 | 3.1 | 1.6 | 2.2 | 2.2 |
Interest coverage, EBITDA / interest (x) (derived) | 2.9 | 3.2 | 4.4 | 4.1 | 3.9 |
Asset turnover (x) (derived, on average assets) | 1.46 | 1.49 | 1.43 | 1.47 | 1.73 |
Debtor days (Screener) | 35 | 40 | 43 | 42 | 44 |
Inventory days (Screener) | 60 | 60 | 81 | 92 | 60 |
Payable days (Screener) | 56 | 44 | 55 | 63 | 62 |
Cash conversion cycle, days (Screener) | 38 | 55 | 69 | 71 | 43 |
Margin Analysis (%) and Per-Share Data
| Metric | Q1 FY2026 | Q2 FY2026 | Q3 FY2026 | Q4 FY2026 | Q1 FY2027 |
|---|---|---|---|---|---|
Revenue | 215.90 | 179.17 | 207.79 | 256.28 | 272.87 |
Operating profit | 11.63 | 9.34 | 12.69 | 13.21 | 20.29 |
Operating margin (%) | 5.39 | 5.21 | 6.11 | 5.15 | 7.44 |
Pre-tax profit | 4.04 | 2.19 | 5.10 | 5.88 | 12.19 |
Net profit | 2.94 | 1.56 | 3.66 | 4.19 | 9.00 |
EPS (INR) | 3.48 | 1.84 | 4.32 | 4.95 | 10.62 |
Revenue by Region (%) and Revenue by Region
| Region | FY2025 | FY2026 |
|---|---|---|
Domestic (India) share of revenue (%) | 82 | 82 |
Export share of revenue (%) | 18 | 18 |
Domestic revenue (INR Cr, derived from share) | 540 | 704 |
Export revenue (INR Cr, derived from share) | 119 | 155 |
Capital Markets
| Item | Value |
|---|---|
Share price | INR 494 |
Market capitalisation | INR 418 crore |
52-week high / low | INR 680 / INR 316 |
Trailing P/E | 22.7 times (trailing EPS INR 21.73) |
Price to book | 1.71 times (book value INR 289 per share) |
Dividend yield | 0.20 percent |
EV/EBITDA (derived) | About 9 times (EV of roughly INR 510 crore using March 2026 net debt; trailing operating profit INR 56 crore) |
EV/Sales (derived) | About 0.56 times (trailing sales INR 916 crore) |
1 Year by Period
| Period | 1 year | 3 years | 5 years |
|---|---|---|---|
Stock price CAGR (%) | 6 | -8 | -19 |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (INR) | 0 | 0 | 0 | 1 | 1 |
Payout ratio (%) | 0 | 0 | 0 | 6 | 7 |
Credit Ratings
| Agency | Instrument | Rating | Date | Action |
|---|---|---|---|---|
Crisil Ratings | Bank facilities, INR 200 crore | Crisil A-/Stable | 2 September 2026 | Assigned |
CARE Ratings | Long-term bank facilities, INR 208.87 crore | CARE BBB+; Stable | 19 December 2025 | Downgraded from A-; Stable |
CARE Ratings | Preference shares, INR 18.50 crore | CARE BBB; Stable | 19 December 2025 | Downgraded from BBB+; Stable (instrument since redeemed) |
CARE Ratings | Bank facilities | CARE A-; Stable | 28 June 2024; 27 June 2025 | Upgraded, then reaffirmed |
CARE Ratings | Bank facilities | CARE BBB+; Stable | 24 August 2022; 7 August 2023 | Assigned, reaffirmed |
Debt Facilities
| Facility | Lender | Amount (INR Cr) | Maturity |
|---|---|---|---|
Fund-based working capital | HSBC | 55 | Revolving |
Fund-based working capital | SVC Co-operative Bank | 70 | Revolving |
Term loan (capex) | HSBC | 60 | 31 May 2031 |
Term loan | HSBC | 4.5 | 30 September 2026 |
Proposed long-term facility | Unallocated | 10.5 | — |
Analyst Conclusions
Management guidance. No numerical guidance has been published in the sources reviewed. Management's qualitative message is efficiency, utilisation and a move toward skin-care and specialty ingredients.
External expectations. Crisil expects FY2027 revenue growth to be driven largely by realisations with steady volumes; operating margin to improve gradually as the multi-purpose plant ramps; net cash accrual above INR 40 crore in FY2027; and capex of INR 50 to 60 crore in FY2027. There is no sell-side consensus.
Bull case
-
Earnings are near a cyclical low and already turning. Q1 FY2027 net profit of INR 9.0 crore is close to three-quarters of all of FY2026, and trailing EPS has recovered to INR 21.73.
-
New capacity changes the mix. A multi-purpose plant plus an R&D centre gives the company, for the first time, the means to sell smaller-volume specialties; Crisil's upgrade trigger of 12 to 14 percent margin shows what a successful shift would look like.
-
The balance sheet can carry the plan. Gearing of 0.43 times, an A- rating, the preference shares redeemed and unused bank lines mean the expansion does not need equity.
Bear case
-
The margin recovery may be inventory, not structure. Crisil says first-quarter gains are temporary, and cost-plus contracts tie profit to feedstock direction.
-
Two customers are the business. At about 71 percent of revenue, a sourcing change at either would outweigh any benefit from new products; the same customers cap pricing.
-
Returns do not cover the cost of capital. ROE has averaged about 7 percent over five years, and another INR 85 to 100 crore is being invested, partly with debt, while project cost estimates already differ between rating agencies. Legal and governance signals (customs penalty naming the CEO, an independent director leaving within a year) add to the discount.
Catalysts and monitorables for the next 12 months
Analyst verdict. Aarti Surfactants is a sound operating business that has not yet shown it can earn an adequate return. Its franchise is real: it supplies India's largest consumer-goods companies from two established plants, its approvals take over a year to replicate, and its lenders now view it as an A-minus credit. Since listing it has cut gearing by more than half and redeemed its legacy preference shares without fresh equity beyond the 2023 rights issue.
The record on profitability is weaker. Revenue has grown about 13 percent a year since FY2021, yet FY2026 net profit of INR 12.3 crore was barely more than half the FY2021 figure. Cost-plus contracts mean growth in sales is mostly growth in feedstock prices, and margin depends on which way those prices are moving. One good year in five does not justify the capital employed, and the share price, down roughly 19 percent a year over five years, reflects that.
What could change the picture is now visible and dated. A multi-purpose plant is due by the end of 2026, an R&D centre is running, a US subsidiary exists, and the company has widened its charter and added scientific expertise to its board. If these lift the specialty share, margins of 8 to 10 percent are plausible and the stock, at about half of sales, would look inexpensive. If they do not, the company will have added debt and depreciation to a commodity base that two customers control.
On balance the evidence supports a cautious, watchful stance. The first-quarter rebound is encouraging but partly transient, and the customs order and board turnover deserve attention. The decisive data points are the next two quarterly margins and the commissioning of the new plant. Until those are in hand, the improvement is in the balance sheet and has yet to reach the income statement.
APPENDIX — DATA GAPS AND VERIFICATION FLAGS
| Item | Status |
|---|---|
| FY2026 Annual Report and AGM presentation full text | details taken from filing summaries |
| Gross profit, five years | — |
| Cash balances FY2022 to FY2025 | — |
| FY2026 short-term and long-term debt split | — |
| Executive and director remuneration | — |
| Top ten shareholders by name | — |
| R&D expenditure, five years; patent count | — |
| Rights issue price and size (2023) | — |
| Exact listing date in July 2020; date of registered office shift to Madhya Pradesh | — |
| Export share for FY2024; country-level revenue | — |
| Capacity by plant; utilisation | — |
| Market size figures for surfactants | omitted |
| Peer financials other than Galaxy Surfactants | — |
| Project cost of ongoing capex | Sources conflict: CARE about INR 85 crore; Crisil INR 100 crore |
| FY2025 EBITDA | Sources conflict: INR 45.4 crore, INR 49.6 to 49.8 crore, and CARE PBILDT INR 34.7 crore, by definition |
| One-year share price return | Sources conflict: +6 percent (Screener) versus −7.37 percent (ScanX) |
| Current statutory auditor and registrar | To be confirmed in FY2026 Annual Report |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure and background | Source |
|---|---|---|---|
Mulesh Manilal Savla | Chairman; Independent Director | On the board since the company's formation period; chaired the 8th AGM | Company website; FY2019 Annual Report |
Nikhil Parimal Desai | CEO and Managing Director; promoter group | Leads the company since demerger; over 20 years in IT, project management and business strategy in pharma and chemicals; reappointed for five years from 20 August 2027 to 19 August 2032 | ScanX; Crisil |
Santosh Madhaorao Kakade | Whole-time Director (Executive Director) | Over three decades in plant operations and process development; reappointed for five years from 20 August 2027; liable to retire by rotation | ScanX |
Chandrakant Vallabhaji Gogri | Non-Executive Director; promoter | Founder and Chairman Emeritus of Aarti Industries | CARE; Crisil |
Parimal Hasmukhlal Desai | Non-Executive Director; promoter group | Co-founder of Aarti Industries and father of the Managing Director; on the board from 1 October 2025 | Crisil; TheCompanyCheck |
Dattatray Sidram Galpalli | Non-Executive Director | Reappointed on retirement by rotation at the 8th AGM | ScanX |
Misha Bharat Gala | Independent Director | Woman independent director | Company website |
Prof. Vandana B. Patravale | Independent Director | Appointed 22 August 2026 for five years to 21 August 2031; Ph.D. in Pharmaceutics; Senior Professor at the Institute of Chemical Technology, Mumbai | ScanX |
Executive Leadership Team
| Name | Title | Notes |
|---|---|---|
Nikhil P. Desai | CEO and Managing Director | See above |
Santosh M. Kakade | Executive Director | See above |
Nitesh Medh | Chief Financial Officer | TheCompanyCheck |
Priyanka Chaurasia | Company Secretary | TheCompanyCheck |
Kanika Rathore | President, Business and Operations | Promoted from Vice President on 22 August 2026 (ScanX) |
Shareholding Trend
| Holder category | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Promoters (%) | 49.81 | 49.92 | 49.88 | 49.84 |
Foreign institutional investors (%) | 0.09 | 0.14 | 0.14 | 0.08 |
Domestic institutional investors (%) | 0.00 | 0.80 | 0.00 | 0.00 |
Government (%) | 0.01 | 0.01 | 0.01 | 0.01 |
Public (%) | 50.10 | 49.13 | 49.98 | 50.07 |
Number of shareholders | 43,091 | 38,548 | 35,669 | 35,149 |
Competitive Landscape
Key Competitors
| Competitor | Home market | Overlap with the company | Relative position |
|---|---|---|---|
Galaxy Surfactants | India | Direct: performance surfactants and specialty care for the same FMCG buyers | Domestic leader; about six times the company's revenue; plants in India, Egypt and the US; 215+ grades |
Godrej Industries (Chemicals) | India | Fatty alcohols and surfactants | Backward integrated into oleochemicals |
BASF | Germany | Full personal and home care ingredient range | Global leader; technology and breadth |
Stepan Company | United States | Anionic surfactants, sulfonation | Global sulfonation specialist |
Clariant | Switzerland | Mild surfactants and specialties | Specialty focus |
Croda International | United Kingdom | Premium personal care actives | High-margin specialist |
Evonik Industries | Germany | Betaines and specialties | Strong in amphoterics |
Solvay / Syensqo | Belgium | Surfactants and polymers for HPC | Global formulator partner |
Dow | United States | Non-ionic surfactants, rheology | Scale petrochemical integration |
Kao | Japan | Fatty alcohol derivatives | Integrated oleochemical player |
Fine Organic, Rossari Biotech | India | Adjacent specialty additives and HPC ingredients | Higher-margin specialty niches |
Peer Comparison FY2026
| Metric | Aarti Surfactants (FY2026) | Galaxy Surfactants (FY2026) |
|---|---|---|
Revenue | INR 859 crore | INR 5,270 crore total income |
Revenue growth | +30 percent | About +25 percent (largely pricing) |
EBITDA | INR 47 crore | INR 497 crore |
EBITDA margin | 5.5 percent | 9.4 percent |
Net profit | INR 12.3 crore | INR 267 crore |
Market capitalisation | About INR 418 crore | About INR 6,500 to 8,000 crore during 2026 |



